Navigation Links
ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
Date:4/3/2008

SAN DIEGO, April 3, 2008 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that Mark Bagnall, a member of the Company's Board of Directors, has joined the Company as Executive Vice President, a newly created position, and Chief Financial Officer. As Executive Vice President, Mr. Bagnall will work with the Company's Chief Executive Officer and President to define the Company's long-term strategy, help oversee internal execution of that strategy and communicate with the Company's stakeholders.

Mr. Bagnall will continue as a member of the Company's Board of Directors, but has resigned his positions on the Company's Audit, Compensation and Nominating & Governance Committees, as well as his position as Chair of the Audit Committee. Jack Lief, currently Chair of the Board of Directors, will increase his involvement with the Company and assume Mr. Bagnall's responsibilities as Chair of the Audit Committee.

The Company also announced that Gregory P. Hanson's employment relationship with the Company ended, effective April 2, 2008. Mr. Hanson joined the Company in December 2006 and previously served as the company's Chief Financial Officer.

"Mark is a proven biotechnology executive and we welcome him to our team," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "His expertise in the public and private sector, as well as his unique perspective as a long-time Board member, will prove invaluable as we advance our product candidates towards commercialization. In addition, we thank Greg for his service to the company, and wish him success in the future."

"This is a great time to be joining the ADVENTRX management team," stated Mr. Bagnall. "The company has made treme
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
3. Eric K. Rowinsky Joins ADVENTRX Board of Directors
4. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
5. ADVENTRX Announces Consolidation of Clinical and Management Positions
6. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
7. ADVENTRX Appoints Vice President of Commercialization
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
11. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SNY) today announced that the Companies intend to use ... disease priority review voucher in connection with the Biologics ... voucher entitles the holder to designate a BLA for ... from the filing date instead of the standard 10-month ...
(Date:7/30/2014)... , July 30, 2014 A ... evaluated the safety and efficacy of CSL Behring,s ... following kidney transplants in highly sensitized patients. C1-INH ... of the complement system. The study ... significant increases in the levels of complement components ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
(Date:7/30/2014)... SEGUNDO, Calif. , July 30, 2014 /PRNewswire/ ... contractor on the Fully Integrated Lifecycle Mission Support ... and Space Administration (NASA). Under the terms of ... Ames Research Center at Moffett Field, Calif. In ... support for bioscience flight development projects on the ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2
... 0 clinical testing has been gaining acceptance and ... development process in the years to come. The ... and technology dependence is also expected to result ... in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There is every ...
... Health Care Business Conference, an MBA-student organized event, will be held ... distinguished speakers and panelists from Healthcare Services, Investment, Pharma, Biotech, and ... ... 10, 2009 -- The 2009 Wharton Health Care Business Conference ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:7/31/2014)... LA Dr. Oren Tessler, Assistant Professor of Clinical ... of Medicine, is part of a team of plastic ... using a method to screen and select patients for ... of the patients who underwent this surgery to decompress ... got a bonus cosmetic eyelid surgery. The study, which ...
(Date:7/31/2014)... NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... and consumers wanting to learn more about its  ... on-air today, July 31 st . ... featured in a segment of NewsWatch, a weekly ... the History Channel, FYI Network today. ...
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... choices for our nation,s schoolchildren is a hot-button issue ... team of researchers from Cornell University have recently identified ... vegetables and salad items. Laura Smith, a researcher ... findings of the study "Convenience Drives Choice in School ...
... Inc. (Nasdaq: OKSB ), ("Southwest"), today announced that it has priced its ... the public of $12.50 per share for net proceeds of approximately ... size of approximately $40 million .  The offering is expected to close ... , , ...
... PHILADELPHIA , April 27 Mondre Energy, Inc. (MEI), a ... Exeter Associates to address a wide range of energy issues on behalf ... Power Plant Research Program works to ensure that Maryland meets ... , , ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: